DexCom (NASDAQ:DXCM) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their ...

Dexcom launched its first over-the-counter continuous glucose monitor called Stelo on Monday. Users can buy a one-month supply online for $99, or sign up for an ongoing subscription at $89 a month.

Oura and Dexcom are partnering on metabolic health — and they mean big business. Dexcom has invested $75 million into Oura to make the deal happen, valuing Oura at $5 billion. That works out to just a ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

DexCom, Inc.’s (NASDAQ:DXCM) third-quarter 2025 revenue reached $1.209 billion, beating the analyst consensus estimate of $1.179 billion. Revenue grew 22% year-over-year on a reported basis and 20% ...

Join Becker’s Healthcare Podcast as we dive into the world of continuous glucose monitoring with Scott Odgers from Dexcom. Discover how CGM devices are transforming healthcare experiences and access, ...

In March, the FDA cleared Dexcom’s Stelo, making it the first glucose biosensor that doesn’t require a prescription. The small, wearable device, worn on the back of the upper arm, is designed for ...